Metastasis and multidrug resistance (MDR) are the main reasons for the poor prognosis of non-small cell lung cancer (NSCLC) patients. The use of biomarkers may contribute to a more accurate prediction of tumor metastasis, a better response to chemotherapy, and better patient survival. Gelsolin-like actin-capping protein (CapG) and gelsolin have been identified as playing important roles in tumor invasion and metastasis. Permeability glycoprotein (P-gp), glutathione S-transferase pi (GSTP1), and topoisomerase-II (Topo-II) are proteins that are closely related to MDR. In this study, we assessed the prognostic significance of CapG and gelsolin (both markers of tumor motility), and of P-gp, GSTP1, and Topo-II (markers of MDR) in NSCLC patients. One hundred and twenty-one patients with pathologically confirmed, resectable NSCLC were included in the study. The expression levels of the five kinds of proteins mentioned above were determined by immunohistochemistry (IHC). The correlation between the clinical characteristics and IHC findings were analyzed. Expression of CapG, gelsolin, and P-gp was found to be associated with an increased risk of death (Hazard Ratio (HR) ¼ 2.799, 95% Confidence Interval (CI) ¼ 1.2705-6.169, P ¼ 0.011; HR ¼ 3.968, 95% CI ¼ 1.811-8.693, P ¼ 0.001; HR ¼ 3.251, 95% CI ¼ 1.456-7.260, P ¼ 0.004, respectively), whereas expression of GSTP1 and Topo-II was not. These results suggest that higher tumor motility and MDR may be important in NSCLC prognosis. Anat Rec, 295:208-214, 2012. V V C 2011 Wiley Periodicals, Inc.Key words: NSCLC; CapG; gelsolin; P-gp; prognosisLung cancer remains the leading cause of cancerrelated deaths in China, in both males and females. The most common form of lung cancer, non-small cell lung cancer (NSCLC), has a 5-year relative survival rate below 70% in patients with Stage I tumors, and below 1% in patients with Stage IV tumors (Jemal et al., 2009). Treatment of patients with NSCLC is governed by various prognostic factors such as surgical stage, histological grade, differentiation, and lymph node metastasis. Nevertheless, the clinical outcome in individual patients is often difficult to predict.The main cause of death from lung cancer is usually related to metastasis and resistance to chemotherapeutics after primary surgery. If prognosis could be determined more precisely before treatment, then patients would be more effectively treated with individualized therapy. Compared with mRNAs, which degrade quickly if samples are not prepared correctly, proteins are more stable and potentially very useful biomarkers. Furthermore, differences in protein expression may reveal information about biological properties of tumors.